Following concerns about the pediatric use of cough and cold medicines, as have been noted in the UK (Marketletter March 31), the health authorities in Australia are taking steps to curb their consumption.
The National Drugs and Poisons Scheduling Committee, part of the Department of Health and Aging, has announced that sedating antihistamines, which are used in many cough and cold medicines, will only be available as prescription medicines for children under two years of age.
This decision follows consideration of these medicines by the NDPSC at its February meeting, and its conclusion that the safety concerns that have arisen with their use outweigh the evidence of the benefit from providing them over-the-counter in pharmacies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze